Breakthrough Study Reveals Insights into Glaucoma Risk Following Bilateral Congenital Cataract Surgery

Written By :  Dr.Niharika Harsha B
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-03-01 19:45 GMT   |   Update On 2024-03-01 19:45 GMT

In a groundbreaking prospective longitudinal cohort study conducted at Zhongshan Ophthalmic Centre, researchers have shed light on the incidence and associated risk factors for developing suspected and definitive glaucoma in children who underwent bilateral congenital cataract (CC) removal. Identifying and understanding the risk factors associated with suspected and definitive glaucoma...

Login or Register to read the full article

In a groundbreaking prospective longitudinal cohort study conducted at Zhongshan Ophthalmic Centre, researchers have shed light on the incidence and associated risk factors for developing suspected and definitive glaucoma in children who underwent bilateral congenital cataract (CC) removal. Identifying and understanding the risk factors associated with suspected and definitive glaucoma post bilateral CC surgery is crucial for mitigating the risk of secondary blindness in children. The study results were published in the British Journal of Ophthalmology. The study, spanning a 5-year follow-up period, aimed to provide valuable insights that could lead to early intervention strategies and reduce the risk of secondary blindness in pediatric patients.

The study, conducted between January 2011 and December 2014, enrolled 351 children (686 eyes) who had undergone bilateral CC removal surgery. The participants were categorized based on postoperative lens status during the 5-year follow-up period: 130 eyes in the aphakia group, 219 in the primary intraocular lens (IOL) implantation group, and 337 in the secondary IOL implantation group.
Key Findings:
  • Suspected and definitive glaucoma manifested at a mean time of 2.84 years postoperatively, with a cumulative incidence of 9.97% (35 of 351 patients).
  • This included 6.12% (42 eyes) for definitive glaucoma and 2.48% (17 eyes) for suspected glaucoma.
  • Microcornea, a family history of CC, and initial anterior vitrectomy were identified as significant risk factors for both suspected and definitive glaucoma.
  • Primary IOL implantation emerged as a potential protective factor, significantly reducing the risk of glaucoma development.
The study emphasizes the critical importance of identifying suspected and definitive glaucoma early in children who undergo bilateral CC surgery. Detection of related risk factors, such as microcornea, CC family history, and initial anterior vitrectomy, should prompt increased vigilance for healthcare providers. Early intervention and treatment strategies can substantially lower the risk of secondary blindness in this vulnerable population. The findings pave the way for more focused clinical trials to further validate the potential protective role of primary IOL implantation. Understanding the impact of lens status on glaucoma risk can lead to refined surgical approaches, ultimately benefiting pediatric patients undergoing CC surgery.
This groundbreaking study not only unravels the intricate relationship between bilateral CC surgery and the risk of glaucoma but also underscores the importance of tailored interventions based on identified risk factors. As researchers delve deeper into the clinical implications, the potential protective role of primary IOL implantation offers a ray of hope for preventing glaucoma-related complications in children. This research serves as a cornerstone for future endeavors aimed at refining clinical practices and ensuring optimal outcomes for pediatric patients undergoing bilateral CC surgery.

Further reading: Wang J, Wu X, Wang Q, et al. Incidence of and risk factors for suspected and definitive glaucoma after bilateral congenital cataract surgery: a 5-year follow-up. Br J Ophthalmol. 2024;108(3):476-483. Published 2024 Feb 21. doi:10.1136/bjo-2022-322589

Tags:    
Article Source : British Journal of Ophthalmology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News